Reducing carbapenem use for low-risk AmpC-producing Enterobacterales: impact of a microbiology comment-based stewardship initiative
Open Access
- 29 October 2026
- journal article
- research article
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e355
Abstract
Background: AmpC B-lactamases cause resistance to broad-spectrum B-lactams with variable expression dependent on bacterial species. Practice remains heterogenous regarding treatment of infections caused by AmpC organisms. This study aimed to assess the impact of a microbiology comment-based stewardship intervention on the definitive treatment of low-risk AmpC-producing Enterobacterales bacteremia. Methods: This was a pre- and posttest quality improvement study conducted at Island Health Authority. A stewardship intervention involving amendment of a microbiology report comment regarding inducible resistance was implemented on February 13, 2023. Patients aged 18 and older with blood cultures growing low-risk AmpC-producing organisms were included. The primary end point of proportion of patients receiving ceftriaxone or piperacillin-tazobactam was compared between pre- (June 2021 to February 2023) and postintervention periods (February 2023 to October 2024). Secondary end points included clinical outcomes, ceftriaxone/piperacilin-tazobactam resistance rates, and C. difficile infection. Results: A total of 56 patients were included (25 preintervention and 31 postintervention). Definitive ceftriaxone/pipercillin-tazobactam antibiotic therapy was prescribed more frequently postintervention compared to preintervention (45.8% vs 5.0%, P < .001). After adjusting for critical illness, patients in the postintervention group had 17.7-fold higher odds (CI 1.9–162.6) of receiving definitive ceftriaxone or piperacillin-tazobactam (PTZ) compared to the preintervention group. No patients required retreatment for the same organism initially cultured, and neither group had ceftriaxone or PTZ resistance documented within 30 days posttreatment completion. Conclusion: The microbiology comment-based antimicrobial stewardship intervention led to increased ceftriaxone and PTZ prescribing for low-risk AmpC-producing Enterobacterales bloodstream infections compared to carbapenems, without affecting patient outcomes and increasing resistance rates.Keywords
This publication has 7 references indexed in Scilit:
- Ceftriaxone versus cefepime or carbapenems for definitive treatment of low-risk AmpC-Harboring Enterobacterales bloodstream infections in hospitalized adults: A retrospective cohort studyDiagnostic Microbiology and Infectious Disease, 2024
- Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative InfectionsClinical Infectious Diseases, 2024
- Leveraging stewardship to promote ceftriaxone use in severe infections with low- and no-risk AmpC EnterobacteralesAntimicrobial Agents and Chemotherapy, 2023
- Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-ResistantAcinetobacter baumannii, andStenotrophomonas maltophiliaInfectionsClinical Infectious Diseases, 2021
- Infections caused by naturally AmpC-producing Enterobacteriaceae: Can we use third-generation cephalosporins? A narrative reviewInternational Journal of Antimicrobial Agents, 2020
- A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant WorldClinical Infectious Diseases, 2019
- Emergence of Antibiotic Resistance during Therapy for Infections Caused by Enterobacteriaceae Producing AmpC β-Lactamase: Implications for Antibiotic UseAntimicrobial Agents and Chemotherapy, 2008